Tirzepatide vs Semaglutide Cost

What the data shows

Across the 16 programmes we price, all-in cost at a 10 mg maintenance dose runs from $215 to $597 for the identical molecule. The spread is overhead, clinical wrap, pharmacy sourcing and margin rather than the medicine.

What to do with it

Price the dose you expect to hold, including every recurring fee, and check the figure against the provider's own page before acting on it. Every programme page here links that page directly.

What we could not establish

Shipping reliability, response times and clinical quality. None is measurable from outside, so none appears in our tables rather than being estimated.

What this changes about the programme you pick

Very little on its own, which is the honest answer. Almost every decision in this market comes back to three questions: what will I pay at the dose I actually hold, who compounds it, and what happens if I stop. A page that does not move one of those three is decoration.

Where this one moves the needle is on the first. Run the figure at your expected maintenance dose rather than the advertised one, and the ranking you were shown elsewhere frequently inverts.

How to check the numbers above

Every figure carries a capture date and an evidence status. Prices marked verified were read on the provider's own page; the rest came from named third-party sources and are treated as indicative. Open the dataset, re-sort it, and see whether our published order reproduces.

If it does not, that is a bug or a lie and you can find it without our help. If our figure and a provider's own page disagree, ours is wrong and we want to know.

What is deliberately absent

Shipping reliability, response times, and whether the clinical oversight is any good. We hold no measurements of those we would defend, so they appear nowhere in our tables rather than being estimated into a score.

That is why there is no rating out of ten on this site. A single number would compress price, disclosure, service and clinical depth into one figure and hide the weighting. We publish the inputs instead so you can weight them yourself.

What the spread tells you

All-in cost at a 10 mg maintenance dose runs from $215 to $597 across the 16 programmes we price. That is the identical molecule from the same category of licensed pharmacy, so the difference is overhead, clinical wrap, sourcing and margin rather than the medicine.

A 2.8-times spread on an identical product is unusual outside markets where buyers cannot easily compare, which is exactly the condition this site exists to remove.

Price the dose you will actually hold

The single most valuable correction anyone reading this can make. Advertised figures describe the 2.5 mg starter dose, which occupies about four weeks of a twelve-month course. Ten of your first twelve months are spent at or near a maintenance dose.

On a dose-scaled programme those are different numbers. On a flat programme they are not, which is the entire argument for flat pricing and the reason it is worth paying a little more at initiation for it.

The verification step most people skip

Ask which pharmacy fills the prescription, by name, then search your state board's licensee register for it. It is free, takes about two minutes, and fewer than a fifth of priced programmes publish enough to let you do it.

A programme that names a pharmacy has given you something checkable. One that describes a category has told you what it is not telling you. One that deflects has answered the question.

Two questions that settle most of it

What will I pay in total in month six at 10 mg, including every fee? A flat, all-inclusive programme answers in one sentence. A split-pricing programme needs three, because the answer depends on whether your insurance pays for the medication. A programme that cannot answer at all has told you something.

Which pharmacy fills it, and is the prescriber licensed in my state? Both are checkable against public registers, both are free, and neither requires you to trust us or the programme.

What a good answer looks like in writing

A figure with a dose attached. A named pharmacy with a state licence number. A cancellation notice period. A statement that the preparation is compounded and not FDA-approved. And a renewal rate that matches the rate you were quoted.

Getting those five in an email before you pay costs nothing and resolves almost every dispute that appears in complaint records for this category. The programmes that answer promptly are, in our reading of the public record, rarely the ones patients later write about.

How current this is

Prices captured 2026-08-05. Every figure on this page carries that date and an evidence status saying whether we read it at the provider or took it from a third party. Pricing in this market has moved repeatedly during 2026, and several large programmes stopped selling compounded tirzepatide entirely.

Treat any comparison older than a month — including this one — as needing a re-check before you act on it. The dataset is republished on every build.

The three numbers worth carrying away

The cheapest verified all-in cost at a maintenance dose: $215 a month, $2,580 for a first year. The share of priced programmes charging a mandatory recurring fee on top of medication: 5 of 16. And the share naming a dispensing pharmacy before purchase: fewer than a fifth.

Those three settle more purchasing decisions than any narrative comparison, and all three are reproducible from the file.

What most published comparisons get wrong about this

They compare advertised figures, which are not comparable to one another. One programme quotes medication only, another bundles a mandatory membership, a third quotes a promotional first month that reverts, a fourth reprices you as the dose climbs, and a fifth charges a programme fee with medication billed separately.

Ranking those five on their headline numbers produces an order that is wrong in a predictable direction: the programmes with the most aggressive fee structures look cheapest.

What this page assumes about you

That you are paying cash, that you will hold a maintenance dose rather than a starter dose, and that a difference of a few hundred dollars across a year is worth an hour of reading. If any of those is wrong, the ordering here changes.

Insurance is the biggest one. A covered prescription under a documented indication beats every cash route on this site, and establishing whether you qualify comes before comparing 16 cash prices spanning $215 to $597.

The bias we can see in our own data

We track what programmes publish, so programmes that publish well look better here than programmes that treat pricing as a sales conversation. That is a real bias and we would rather name it than pretend the dataset is neutral.

It cuts a defensible way — a programme unwilling to state a price before an intake has made a choice you should notice — but it is a bias, and 16 tracked programmes appear here with an explanation instead of a number because of it.

What we deliberately do not measure

Shipping reliability, response times, and whether the clinical oversight is any good. None is observable from outside without enrolling, and we did not enrol.

That absence is why there is no rating out of ten anywhere here. A single score would compress price, disclosure, service and clinical depth into one figure and hide the weighting — which is precisely the trick that makes comparison sites feel authoritative while telling you less than a table would.

The usable proxy is what a programme publishes before it has your money, and that is what every disclosure column here records.

The switching cost nobody prices

Moving programmes for a modest saving carries two costs a table cannot show: a supply gap while a new intake is reviewed, and a new prescriber restarting titration rather than continuing your dose.

The second is expensive. Eight to twelve weeks back through the ladder erases most of what a year's saving would have bought. Ask for dose continuation in writing before cancelling anything, and do not cancel until the new programme has shipped.

What stopping does, and why it belongs in a cost calculation

The withdrawal evidence for this drug class is consistent: substantial weight regain follows discontinuation, because the drug suppresses appetite while it is being taken rather than resetting a set point. That is a pharmacological property, not a failure of willpower.

Read as a budgeting question, it means the relevant number is not what a first year costs but what a sustainable year costs, repeated. A programme you can afford for three years at a maintenance dose is a better clinical bet than one you can afford for eight months, even if the second is cheaper on the month you enrol.

Why the same molecule sells across a fifteenfold range

The active ingredient is identical whether it arrives as Zepbound at list price or as a compounded preparation at $215 a month. What differs is everything around it: pre-market review, manufacturing under a federal quality system, supply-chain traceability, cold-chain validation, pharmacovigilance and the commercial cost of bringing a drug to market at all.

That is the trade a compounded route asks you to make, and it is a real one in both directions. The approved product carries assurances the compounded one does not. The compounded one is accessible to people for whom the approved product is not, which is not a trivial benefit when the alternative is no treatment.

What is not defensible is presenting the two as equivalent. A compounded preparation is not a cheaper version of Zepbound; it is a different regulatory object containing the same molecule.

The pharmacology behind the fees

Tirzepatide is dosed weekly, ships refrigerated and must not freeze. Those three facts explain most of the fee structures in this market. Weekly dosing means monthly fulfilment cycles and recurring shipping. Refrigeration means insulated packaging, coolant and expedited carriage. Not freezing means the winter and summer failure modes are different and both cost money to mitigate.

A programme charging nothing for shipping has absorbed that cost into the medication price rather than eliminated it. A programme itemising it has not necessarily made you worse off. The only comparison that survives either structure is the all-in monthly figure, which is why it is the only figure this site ranks on.